Cybear, Mediconsult go public with merger plans

Article

Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of

Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of Cybear stock for each share of Mediconsult. Subject to regulatory and shareholder approval, the firms expect to complete the merger in the second quarter. In the meantime, Cybear has agreed to provide interim financing to Mediconsult and to restructure its own company to reduce operating expenses. In a completely separate transaction, Cybear and Mediconsult's Physicians' Online Internet portal have entered into a strategic alliance.

In related news, Mediconsult plans to appeal Nasdaq's decision to delist Mediconsult's stock for not meeting the minimum net tangible assets requirement. Whether Mediconsult's potential delisting will affect the Cybear deal remains an open question. At press time, both Cybear and Mediconsult were trading well under $1 per share.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.